Esketamine Nasal Spray is a prescription medication formulated for the treatment of adults with treatment-resistant depression (TRD) and, in some cases, major depressive disorder with acute suicidal ideation or behavior. Derived from ketamine, esketamine works differently from traditional antidepressants by targeting the NMDA receptor in the brain, helping to restore synaptic connections that influence mood and emotional regulation.

Unlike standard oral antidepressants that may take weeks to show effects, esketamine nasal spray is known for its rapid-acting mechanism, with some patients experiencing symptom improvement within hours to days under medical supervision. It is administered intranasally in a certified healthcare setting, ensuring proper monitoring for safety and effectiveness.

Key Features:

• FDA-approved for treatment-resistant depression (where applicable by region)

• Rapid-acting mechanism targeting glutamate pathways

• Administered under healthcare professional supervision

• Used in conjunction with an oral antidepressant

• Structured Risk Evaluation and Mitigation Strategy (REMS) program in certain countries

Esketamine nasal spray represents an innovative advancement in depression treatment, particularly for individuals who have not responded adequately to multiple antidepressant therapies. Because of its potential side effects—including dissociation, increased blood pressure, and sedation—administration requires observation in a certified medical facility.